For emerging markets worldwide, the average value of enterprise value to earnings before interest, tax, depreciation and amortization (EV/EBITDA) in the health and pharmaceuticals sector as of 2025 was a multiple of approximately 24.7x. Companies operating in the drugs (biotechnology) industry saw the highest valuation multiple with EV/EBITDA valued at 157.8x.
Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2025, by industry
Adjust the presentation of the statistic and data points.
Share the statistic on social media channels or embed the statistic in your
website using "Embed Code", where available.
Cite this statistic and select one of the following formats: APA, Chicago, Harvard, MLA & Bluebook.
Print the statistic including description and metadata.
Chart type
Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2025, by industry
Share this statistic
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Values are as of January each year. A total of 1,992 companies were included in the calculation for 2025.
Enterprise value = Market value of equity + Market value of debt - Cash. EBITDA = Estimated by adding depreciation and amortization back to operating income (EBIT).
Emerging markets include; Anguilla, Antigua & Barbuda, Argentina, Azerbaijan, Bahamas, Bahrain, Bangladesh, Bermuda, Botswana, Brazil, British Virgin Islands, Bulgaria, Burkina Faso, Cambodia, Cameroon, Cayman Islands, Chile, China, Colombia, Costa Rica, Croatia, Curaçao, Dominican Republic, Ecuador, Egypt, Estonia, Falkland Islands, Gabon, Ghana, Greenland, Hong Kong, India, Indonesia, Israel, Ivory Coast, Jamaica, Jordan, Kazakhstan, Kenya, Kuwait, Kyrgyzstan, Laos, Latvia, Lebanon, Lithuania, Macau, Macedonia, Malawi, Malaysia, Mali, Marshall Islands, Mauritius, Mexico, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Netherlands Antilles, Niger, Nigeria, Oman, Pakistan, Palestinian Authority, Panama, Papua New Guinea, Peru, Philippines, Qatar, Romania, Russia, Saint Lucia, Saudi Arabia, Senegal, Serbia, Singapore, Slovakia, Slovenia, Solomon Islands, South Africa, South Korea, Sri Lanka, Sudan, Taiwan, Tanzania, Thailand, Togo, Trinidad & Tobago, Tunisia, Turks & Caicos Islands, Uganda, Ukraine, United Arab Emirates, Uruguay, Vietnam, Zambia, Zimbabwe.
Figures for years 2019 to 2024 were previously published by the source.
Learn more about how Statista can support your business.
Leonard N. Stern School of Business. (January 5, 2025). Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2025, by industry [Graph]. In Statista. Retrieved March 14, 2025, from https://www.statista.com/statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
Leonard N. Stern School of Business. "Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2025, by industry." Chart. January 5, 2025. Statista. Accessed March 14, 2025. https://www.statista.com/statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
Leonard N. Stern School of Business. (2025). Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2025, by industry. Statista. Statista Inc.. Accessed: March 14, 2025. https://www.statista.com/statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
Leonard N. Stern School of Business. "Average Ev/Ebitda Multiples in The Health and Pharmaceuticals Sector in Emerging Markets Worldwide from 2019 to 2025, by Industry." Statista, Statista Inc., 5 Jan 2025, https://www.statista.com/statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
Leonard N. Stern School of Business, Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2025, by industry Statista, https://www.statista.com/statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/ (last visited March 14, 2025)
Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2025, by industry [Graph], Leonard N. Stern School of Business, January 5, 2025. [Online]. Available: https://www.statista.com/statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
